Valuation: Immatics N.V.

Market Cap 1.37B 1.21B 1.11B 1.04B 1.95B 129B 1.99B 13.36B 5.18B 63.68B 5.14B 5.03B 222B P/E 2026 *
-4.89x
P/E 2027 * -5.33x
Enterprise Value 1.08B 948M 874M 818M 1.53B 102B 1.56B 10.51B 4.07B 50.07B 4.04B 3.96B 174B EV / Sales 2026 *
23.5x
EV / Sales 2027 * 20.2x
Free-Float
74.82%
Yield 2026 *
-
Yield 2027 * -
1 day+1.11%
1 week+5.25%
Current month-12.95%
1 month-13.77%
3 months+8.91%
6 months-3.38%
Current year-4.57%
1 week 9.7
Extreme 9.7
10.22
1 month 8.76
Extreme 8.76
11.77
Current year 8.55
Extreme 8.55
11.94
1 year 5.05
Extreme 5.05
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
16.3
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 31/12/2018
Director of Finance/CFO 57 30/09/2025
Chief Tech/Sci/R&D Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 51 30/06/2020
Chairman 70 30/09/2012
Director/Board Member 72 30/06/2020
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Director

48,000 0.0358%
06-15Free

Director

48,000 0.0358%
06-15Free

Director

48,000 0.0358%
Change 5-day change 1-year change 3-year change Capi.($)
+1.11%+5.25%+84.19%-13.92% 1.35B
-7.92%-4.05%+53.28%+106.11% 57.55B
+8.55%+17.52%+72.65%+82.31% 47.08B
-0.45%-2.18%-14.16%-15.80% 22.92B
+1.28%+5.09%-2.30%+418.34% 22.14B
+3.33%+8.76%+30.43%-12.82% 16.33B
-0.15%+4.15%+27.79%-34.84% 15.97B
+2.98%+0.82%+15.64%+166.21% 12.9B
+5.94%+14.85%+134.05%+296.09% 12.85B
-0.71%+1.98%+78.88%+114.48% 11.84B
Average +1.40%+6.00%+48.04%+110.62% 22.09B
Weighted average by Cap. +0.56%+5.38%+45.37%+114.98%

Financials

2026 *2027 *
Net sales 45.91M 40.42M 37.28M 34.87M 65.33M 4.33B 66.55M 448M 174M 2.13B 172M 169M 7.43B 50.63M 44.57M 41.11M 38.45M 72.04M 4.77B 73.39M 494M 191M 2.35B 190M 186M 8.19B
Net income -279M -245M -226M -212M -397M -26.28B -404M -2.72B -1.05B -12.97B -1.05B -1.02B -45.11B -281M -248M -228M -214M -400M -26.51B -408M -2.74B -1.06B -13.08B -1.06B -1.03B -45.5B
Net Debt -293M -258M -238M -222M -416M -27.58B -424M -2.86B -1.11B -13.6B -1.1B -1.07B -47.33B -346M -305M -281M -263M -492M -32.61B -502M -3.38B -1.31B -16.09B -1.3B -1.27B -55.97B
Logo Immatics N.V.
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Employees
678
Date Price Change Volume
24/06/26 US$10.02 +1.11% 675,906
23/06/26 US$9.910 +1.33% 347,256
22/06/26 US$9.780 0.00% 553,614
18/06/26 US$9.780 +2.73% 438,423
17/06/26 US$9.520 +4.73% 292,980
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
10.02USD
Average target price
18.78USD
Spread / Average Target
+87.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock